Health Care • Biotechnology: Pharmaceutical Preparations
$288.62 ▲ +3.14
(+1.10%)
MKT CAP: $8.06B • VOL: 508.6K
52W L $154 52W H $393
PRAX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $8.6M | $2.4M |
| YoY Revenue Growth % | — | +249.5% | — |
| Gross Profit | $0 | $3.8M | $1.1M |
| Gross Margin % | — | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$326.2M | -$200.2M | -$126.4M |
| Operating Margin % | — | -2340.3% | -5164.4% |
| Net Income (GAAP) | -$303.0M | -$183.0M | -$123.0M |
| EBITDA (Normalized) | -$326.2M | -$200.2M | -$126.3M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$249.1M | -$131.8M | -$111.1M |
| Capital Expenditures (CapEx) | $56.0K | $0 | $110.1K |
| Free Cash Flow (FCF) | -$249.1M | -$131.8M | -$111.2M |
| FCF Margin % | — | -1540.5% | -4546.2% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -3.7% |
| Cash & Short-Term Equivalents | $357.3M | $215.4M | $487.5M |
| Total Debt (Short + Long Term) | $26.9M | $16.9M | $1.04B |
| Total Stockholders' Equity | $878.1M | $445.4M | $2.13B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PRAX.